Expert Insights

At the 2023 ASCO Annual Meeting, Helene Blons, PhD, PharmD, discusses results from an abstract addressing the impact of BRCA1 and RAD51 methylation on the efficacy of olaparib plus bevacizumab maintenance treatment, from the...

Daniel Gomez, MD, summarizes his argument against prophylactic cranial irradiation for patients with small-cell lung cancer, a stance he defended in a debate session at the Great Debates and Updates in Lung Cancer conference in Chicago,...

At the 2023 Great Debates and Updates in Lung Cancer in Chicago, Illinois, Corey Langer, MD, Abramson Cancer Center, University of Pennsylvania, discussed how to best care for the elderly patient population, as well and patients with...

Uday Popat, MD, presented data from a clinical trial that indicated the fractionation of busulfan reduced toxicities among patients with AML and MDS. This data was presented at the 2023 ASCO annual meeting.

At the 2023 ASCO annual meeting, Won Jin Jeon, MD, presented data from a meta-analysis that explored the prognostic value of identifying BCL6 and CD10 variants in the treatment and management of mantle cell lymphoma.

On site at ASCO 2023, Dr Lars Henrik Jensen shares results from the phase 3 NeoCol trial evaluating the addition of neoadjuvant chemotherapy to initial surgery for patients with locally advanced colon cancer.

At the 2023 ASCO annual meeting, Carolina Schinke, MD, discussed updated results from the MonumenTAL-1 trial which indicated that patients with heavily pretreated R/R multiple myeloma had impressive responses to treatment with talquetamab.

Lorenzo Falchi, MD presents extended follow-up from a pivotal phase 2 study on CD20-CD3 bispecific antibody glofitamab monotherapy for patients with R/R DLBCL.

Michael Castro, MD, discusses the results of a retrospective study evaluating the effect proton pump inhibition use may have on survival outcomes of patients with glioblastoma.

Niels W.C.J. van de Donk, MD, PhD, presents 2-year follow-up results from the MajesTEC-1 trial, which indicated that teclistamab demonstrated safety and efficacy among heavily pre-treated patients with R/R multiple myeloma.